EWTX PEER ANALYSIS

Edgewise Therapeutics Inc — metric-by-metric comparison with peers and the industry median

EWTXEdgewise Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
EWTXIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
EWTX+204.1%TLX-29.5%MSB+27.6%CSL-48.2%
Year-to-Date (YTD)
EWTX+59.4%TLX+50.7%MSB-24.3%CSL-28.5%

Key Metric Comparison

P/E

Lower is better
EWTXTLXMSBCSL29.44Median 17.91

ROE

Higher is better
EWTX-38.1%TLX-1.8%MSB-11.3%CSL7.7%Median -47.5%

Net Margin

Higher is better
EWTXTLX-0.9%MSB-115.3%CSL9.2%Median -125.7%

Revenue Growth

Higher is better
EWTX-100.0%TLX56.3%MSB410.4%CSL4.8%Median 5.1%

All Metrics

Valuation
MetricEWTXTLXMSBCSLInd. Median
P/E29.4417.91
P/B8.596.372.203.51
EV/EBITDA120.1410.2114.82
P/S3.2431.612.6210.89
Financial Health
MetricEWTXTLXMSBCSLInd. Median
Current Ratio22.611.432.575.90
Debt/Equity0.8%112.3%67.4%10.9%
NetDebt/EBITDA2.8213.132.221.15
Profitability
MetricEWTXTLXMSBCSLInd. Median
Net Margin-0.9%-115.3%9.2%-125.7%
ROE-38.1%-1.8%-11.3%7.7%-47.5%
ROA-36.2%-0.7%-8.6%3.8%-35.8%
EBITDA Margin3.0%-76.6%32.8%-105.8%
Growth + Dividend
MetricEWTXTLXMSBCSLInd. Median
Rev. Growth-100.0%56.3%410.4%4.8%5.1%
NI Growth-39.4%12.1%
Div. Yield0.0%2.5%0.2%
Payout0.0%103.1%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on EWTX

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.